Literature DB >> 10799723

Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology.

C Grau1, L V Johansen, J Jakobsen, P Geertsen, E Andersen, B B Jensen.   

Abstract

BACKGROUND AND
PURPOSE: The management of patients with cervical lymph node metastases from unknown primary tumours is a major challenge in oncology. This study presents data collected from all five oncology centres in Denmark.
MATERIAL AND METHODS: Of the 352 consecutive patients with squamous cell or undifferentiated tumours seen from 1975 to 1995, a total of 277 (79%) were treated with radical intent. The general treatment policy at all centres during the entire study period has been to treat all suitable candidates with radiotherapy to both sides of the neck and include elective irradiation of the mucosal sites in nasopharynx, and larynx, hypopharynx and larynx (81%). Irradiation of the ipsilateral neck only was done in 26 patients (10%). Radical surgery was the only treatment in 23 N1-N2 patients (9%).
RESULTS: The 5-year estimates of neck control, disease-specific survival and overall survival for radically treated patients were 51, 48 and 36%, respectively. The emergence of the occult primary was observed in 66 patients (19%). About half of the emerging primaries were within the head and neck region with oropharynx, hypopharynx and oral cavity being the most common sites. Emerging primaries outside the head and neck region were primarily located in the lung (19 patients) and oesophagus (five patients). The frequency of emerging primary in the head and neck was significantly higher in patients treated with surgery alone, the actuarial risks at 5-year being 54+/-1% (no RT) vs. 15+/-3% (with RT), P<0.0001. The most important factor for neck control was nodal stage (5-year estimates 69% (N1), 58% (N2) and 30% (N3)). Other important parameters for neck control and disease-specific survival included haemoglobin, gender and overall treatment time. Patients treated with ipsilateral radiotherapy had a relative risk of recurrence in the head and neck region of 1.9 compared with patients treated to both neck and mucosa. At 5 years, the estimated control rates were 27% (ipsilateral) and 51% (bilateral; P=0.05). The 5-year disease-specific survival estimates were 28 and 45%, respectively (P=0.10).
CONCLUSIONS: This study has confirmed that patients with neck node metastases from occult head and neck cancer have clinical features and prognosis similar to other head and neck malignancies. Extensive irradiation to both sides of the neck and the mucosa in the entire pharyngeal axis and larynx resulted in significantly less loco-regional failures compared with patients treated with ipsilateral techniques, but only a trend towards better survival. A prospective randomized trial is required to determine the optimal strategy in terms of locoregional control, survival and morbidity.

Entities:  

Mesh:

Year:  2000        PMID: 10799723     DOI: 10.1016/s0167-8140(00)00172-9

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  74 in total

1.  Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy.

Authors:  Candan Demiroz; Jeffrey M Vainshtein; Georgios V Koukourakis; Orit Gutfeld; Mark E Prince; Carol R Bradford; Gregory T Wolf; Scott McLean; Francis P Worden; Douglas B Chepeha; Matthew J Schipper; Jonathan B McHugh
Journal:  Head Neck       Date:  2013-11-18       Impact factor: 3.147

2.  Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis.

Authors:  Müjdat Yildirim; Jens Müller von der Grün; Ria Winkelmann; Emmanouil Fokas; Franz Rödel; Hanns Ackermann; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2017-01-31       Impact factor: 3.621

3.  Iliac lymph node metastasis of an unknown primary tumor: report of a case.

Authors:  Satoru Matsuyama; Yuji Nakafusa; Masayuki Tanaka; Yukie Yoda; Daisuke Mori; Kohji Miyazaki
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 4.  Sex-specific aspects of tumor therapy.

Authors:  Kerstin Borgmann; Ekkehard Dikomey; Cordula Petersen; Petra Feyer; Ulrike Hoeller
Journal:  Radiat Environ Biophys       Date:  2009-02-26       Impact factor: 1.925

Review 5.  [Radiotherapeutic concepts in cancer of unknown primary site].

Authors:  D Krug; J Debus; F Sterzing
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

6.  Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database.

Authors:  Huaising C Ko; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Gregory K Hartig; Paul M Harari; Matthew E Witek
Journal:  Head Neck       Date:  2017-07-24       Impact factor: 3.147

7.  Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.

Authors:  Toshiya Maebayashi; Naoya Ishibashi; Takuya Aizawa; Masakuni Sakaguchi; Tsutomu Saito; Jiro Kawamori; Yoshiaki Tanaka; Yukari Hirotani; Taku Homma
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

8.  What Is New in the World Health Organization 2017 Histopathology Classification?

Authors:  Adel K El-Naggar
Journal:  Curr Treat Options Oncol       Date:  2017-07

9.  Metastatic squamous cell carcinoma neck with occult primary: A retrospective analysis.

Authors:  Pragya Shukla; Deepak Gupta; Shyam Singh Bisht; Mohan Chand Pant; Madan Lal Bhatt; Kirti Srivastava; Mahendra Pal Singh Negi
Journal:  Indian J Med Paediatr Oncol       Date:  2009-10

10.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.